Publications by authors named "U Wadia"
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Article Synopsis
- COVID-19 vaccination in Australia began in February 2021, with initial vaccines requiring two doses; booster vaccinations are now being recommended to maintain immunity.
- The PICOBOO trial is a multi-site study that tests various COVID-19 booster vaccines in children and adults, looking at their effectiveness and safety across different vaccination histories and age groups.
- This adaptive trial structure allows for rapid adjustments to research elements, helping to explore the best approaches for combating COVID-19 variants and assessing new vaccines as they are introduced.
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Methods: Immunocompetent adults who received any first booster ≥three months prior were eligible.
Background: Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.
Objective: To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.
Objectives: Bacille Calmette-Guérin (BCG) vaccine has immunomodulatory effects that may provide protection against unrelated infectious diseases. We aimed to determine whether BCG vaccination protects adults against COVID-19.
Design: Phase III double-blind randomised controlled trial.